Private Placement

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

Central Florida's first new community bank in a decade, Portrait Bank, combines a powerhouse board with AI tech to challenge the region's financial giants.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

Diagnostic leader Bracco enters the cell therapy market with BubbleGen, a novel microbubble tech that promises to streamline complex manufacturing.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

A $33M C-PACE deal for a Deepak Chopra-affiliated resort shows how innovative financing is reshaping real estate development in a tight market.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

A new firm will underwrite a $400M fund, signaling a shift in patent finance toward specialized expertise and empowering small inventors.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

Giyani Metals' high-purity manganese meets quality standards from US tech leader C4V, a crucial step in building a non-Chinese battery supply chain.

Enlight Renewable Energy posts strong Q1 results, with underlying profits surging 76% despite a misleading net income dip, and reaffirms its 2026 outlook.

neurocare's TMS device approval marks a major shift in the Kingdom's approach to depression, prioritizing non-invasive, tech-driven solutions.

The clean energy vehicle company is assembling a top-tier team to develop hydrogen-powered drones, aiming for a slice of the $182 billion UGV market.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

The cloud storage firm topped Q1 estimates and turned a non-GAAP profit, crediting a surge in AI clients drawn to its low-cost, high-performance data platform.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

A junior miner strikes bonanza-grade silver and critical cobalt in a historic district, positioning itself to capitalize on a sixth straight year of market deficits.

With new backing from Bain Capital and Sixth Street, the $1.7B remodeler aims to expand its national footprint and tech-driven, people-first business model.

Scott Drennan takes the helm at Otto Aerospace, tasked with turning the visionary, ultra-efficient Phantom 3500 jet from concept to certified reality.